Retrospective review of MET gene mutations

Maryam Zenali, James DeKay, Zesheng Liu, Stanley Hamilton, Zhuang Zuo, Xinyan Lu, Rania Bakkar, Gordon Mills, Russell Broaddus

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

C-MET proto-oncogene is a tyrosine kinase situated on chromosome 7. C-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) play a role in proliferation, differentiation and organ development. C-MET genetic aberrations are found associated with driving tumorigenesis. In this retrospective study, we reviewed molecular analysis data gathered from a cancer institute during a two-year period (2010-2012). Upon detection of tumors harboring c-MET mutations, we determined the status of the other mutations tested and evaluated c-MET expression by fluorescent in-situ hybridization (FISH). Our search resulted in identification of 134 c-MET mutations, 44% of which had mutations of at least one of the other genes tested. No c-MET expression aberrancy was detected in this subset by FISH. Survival amongst the patients with surgically resected metastatic colorectal cancers (CRC) was slightly better in those with only a c-MET mutation compared to those with no mutation detected, although the difference was not statistically significant. When c-MET inhibition becomes an integrated part of chemotherapy practice, our observed frequency of co-mutations will be an argument for utilizing c-MET targeted treatment in combination with other targeted drugs and therapeutic strategies. Larger studies can aid to further parse out c-MET prognostic and therapeutic significance.

Original languageEnglish (US)
Pages (from-to)533-541
Number of pages9
JournalOncoscience
Volume2
Issue number5
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Mutation
Genes
Hepatocyte Growth Factor
Fluorescence In Situ Hybridization
Chromosomes, Human, Pair 7
Proto-Oncogenes
Mutation Rate
Protein-Tyrosine Kinases
Colorectal Neoplasms
Neoplasms
Carcinogenesis
Therapeutics
Retrospective Studies
Ligands
Drug Therapy
Survival
Pharmaceutical Preparations

Keywords

  • C-MET
  • Co-mutations
  • FISH
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zenali, M., DeKay, J., Liu, Z., Hamilton, S., Zuo, Z., Lu, X., ... Broaddus, R. (2015). Retrospective review of MET gene mutations. Oncoscience, 2(5), 533-541. https://doi.org/10.18632/oncoscience.161

Retrospective review of MET gene mutations. / Zenali, Maryam; DeKay, James; Liu, Zesheng; Hamilton, Stanley; Zuo, Zhuang; Lu, Xinyan; Bakkar, Rania; Mills, Gordon; Broaddus, Russell.

In: Oncoscience, Vol. 2, No. 5, 01.01.2015, p. 533-541.

Research output: Contribution to journalArticle

Zenali, M, DeKay, J, Liu, Z, Hamilton, S, Zuo, Z, Lu, X, Bakkar, R, Mills, G & Broaddus, R 2015, 'Retrospective review of MET gene mutations', Oncoscience, vol. 2, no. 5, pp. 533-541. https://doi.org/10.18632/oncoscience.161
Zenali M, DeKay J, Liu Z, Hamilton S, Zuo Z, Lu X et al. Retrospective review of MET gene mutations. Oncoscience. 2015 Jan 1;2(5):533-541. https://doi.org/10.18632/oncoscience.161
Zenali, Maryam ; DeKay, James ; Liu, Zesheng ; Hamilton, Stanley ; Zuo, Zhuang ; Lu, Xinyan ; Bakkar, Rania ; Mills, Gordon ; Broaddus, Russell. / Retrospective review of MET gene mutations. In: Oncoscience. 2015 ; Vol. 2, No. 5. pp. 533-541.
@article{eb9f69d9b363463db5776f2b43002931,
title = "Retrospective review of MET gene mutations",
abstract = "C-MET proto-oncogene is a tyrosine kinase situated on chromosome 7. C-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) play a role in proliferation, differentiation and organ development. C-MET genetic aberrations are found associated with driving tumorigenesis. In this retrospective study, we reviewed molecular analysis data gathered from a cancer institute during a two-year period (2010-2012). Upon detection of tumors harboring c-MET mutations, we determined the status of the other mutations tested and evaluated c-MET expression by fluorescent in-situ hybridization (FISH). Our search resulted in identification of 134 c-MET mutations, 44{\%} of which had mutations of at least one of the other genes tested. No c-MET expression aberrancy was detected in this subset by FISH. Survival amongst the patients with surgically resected metastatic colorectal cancers (CRC) was slightly better in those with only a c-MET mutation compared to those with no mutation detected, although the difference was not statistically significant. When c-MET inhibition becomes an integrated part of chemotherapy practice, our observed frequency of co-mutations will be an argument for utilizing c-MET targeted treatment in combination with other targeted drugs and therapeutic strategies. Larger studies can aid to further parse out c-MET prognostic and therapeutic significance.",
keywords = "C-MET, Co-mutations, FISH, Targeted therapy",
author = "Maryam Zenali and James DeKay and Zesheng Liu and Stanley Hamilton and Zhuang Zuo and Xinyan Lu and Rania Bakkar and Gordon Mills and Russell Broaddus",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncoscience.161",
language = "English (US)",
volume = "2",
pages = "533--541",
journal = "Oncoscience",
issn = "2331-4737",
publisher = "Impact Journals",
number = "5",

}

TY - JOUR

T1 - Retrospective review of MET gene mutations

AU - Zenali, Maryam

AU - DeKay, James

AU - Liu, Zesheng

AU - Hamilton, Stanley

AU - Zuo, Zhuang

AU - Lu, Xinyan

AU - Bakkar, Rania

AU - Mills, Gordon

AU - Broaddus, Russell

PY - 2015/1/1

Y1 - 2015/1/1

N2 - C-MET proto-oncogene is a tyrosine kinase situated on chromosome 7. C-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) play a role in proliferation, differentiation and organ development. C-MET genetic aberrations are found associated with driving tumorigenesis. In this retrospective study, we reviewed molecular analysis data gathered from a cancer institute during a two-year period (2010-2012). Upon detection of tumors harboring c-MET mutations, we determined the status of the other mutations tested and evaluated c-MET expression by fluorescent in-situ hybridization (FISH). Our search resulted in identification of 134 c-MET mutations, 44% of which had mutations of at least one of the other genes tested. No c-MET expression aberrancy was detected in this subset by FISH. Survival amongst the patients with surgically resected metastatic colorectal cancers (CRC) was slightly better in those with only a c-MET mutation compared to those with no mutation detected, although the difference was not statistically significant. When c-MET inhibition becomes an integrated part of chemotherapy practice, our observed frequency of co-mutations will be an argument for utilizing c-MET targeted treatment in combination with other targeted drugs and therapeutic strategies. Larger studies can aid to further parse out c-MET prognostic and therapeutic significance.

AB - C-MET proto-oncogene is a tyrosine kinase situated on chromosome 7. C-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) play a role in proliferation, differentiation and organ development. C-MET genetic aberrations are found associated with driving tumorigenesis. In this retrospective study, we reviewed molecular analysis data gathered from a cancer institute during a two-year period (2010-2012). Upon detection of tumors harboring c-MET mutations, we determined the status of the other mutations tested and evaluated c-MET expression by fluorescent in-situ hybridization (FISH). Our search resulted in identification of 134 c-MET mutations, 44% of which had mutations of at least one of the other genes tested. No c-MET expression aberrancy was detected in this subset by FISH. Survival amongst the patients with surgically resected metastatic colorectal cancers (CRC) was slightly better in those with only a c-MET mutation compared to those with no mutation detected, although the difference was not statistically significant. When c-MET inhibition becomes an integrated part of chemotherapy practice, our observed frequency of co-mutations will be an argument for utilizing c-MET targeted treatment in combination with other targeted drugs and therapeutic strategies. Larger studies can aid to further parse out c-MET prognostic and therapeutic significance.

KW - C-MET

KW - Co-mutations

KW - FISH

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84958529540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958529540&partnerID=8YFLogxK

U2 - 10.18632/oncoscience.161

DO - 10.18632/oncoscience.161

M3 - Article

AN - SCOPUS:84958529540

VL - 2

SP - 533

EP - 541

JO - Oncoscience

JF - Oncoscience

SN - 2331-4737

IS - 5

ER -